#Israel #AI Technology #Tel Aviv #Fertility Treatment #FertilAI

FertilAI Achieves Pioneering CE Mark

FertilAI has reached a significant milestone in the field of reproductive health by securing the world's first CE mark for its avant-garde artificial intelligence (AI) tools designed for optimizing fertility treatment cycles. This achievement was announced on April 15, 2026, and marks a pivotal moment for healthcare technology in the fertility sector.

The Innovative Solution

The CE marking indicates that FertilAI's predictive AI platforms, specifically StimAI and OvuPredict, meet stringent requirements set forth by the EU Medical Device Regulation (EU MDR). These groundbreaking tools offer fertility clinics a means to discern optimal treatment timings while enhancing overall clinical decision-making processes. By utilizing extensive datasets from over 100,000 treatment cycles, FertilAI's algorithms assist doctors in making informed and timely decisions during crucial treatment phases.

StimAI (EU MDR Class IIa): This advanced algorithm estimates the expected number of mature oocytes to be retrieved based on varying trigger timings. This capability enables physicians to strategize effective treatment plans for In Vitro Fertilization (IVF) procedures while simultaneously balancing the operational workload of IVF laboratories.

OvuPredict (EU MDR Class I): This innovative tool predicts natural ovulation cycles up to six days in advance, facilitating improved scheduling for intrauterine insemination (IUI) and frozen embryo transfers (FET). Such proactive predictions can significantly enhance the chances of pregnancy while also streamlining patient monitoring processes.

Transforming Fertility Clinics

The integration of FertilAI's tools into existing electronic medical record (EMR) systems ensures that clinics have seamless access to intelligent AI resources without the need for major overhauls in their operations. FertilAI’s CEO, Rohi Hourvitz, emphasized that achieving CE marking validates their technology’s capability to elevate clinical decision-making while concurrently optimizing clinic operations. Moreover, this innovation aims to alleviate the rising issue of infertility, which is further exacerbated by a global shortage of medical professionals in this field.

Addressing Global Fertility Challenges

With infertility rates climbing worldwide, FertilAI’s solutions not only help clinics expand their operational capacity but also enhance the patient experience. As noted by Hourvitz, facilitating increased access to fertility treatments is imperative amid increasing costs and extended wait times. His vision succinctly outlines the commitment to making fertility journeys smoother for patients, regardless of their circumstances.

About FertilAI

FertilAI is at the forefront of redefining fertility treatments through technological innovations. Founded by a team that includes clinical specialists and tech experts, the company focuses on employing cutting-edge AI advancements to bolster clinical effectiveness and improve patient interactions. Their technologies have gained recognition in reputable scientific studies, published in esteemed journals like Fertility and Sterility and Nature Scientific Reports. Through ongoing randomized controlled trials, FertilAI continues to validate its healthcare innovations.

For more information, please visit FertilAI's website.

Conclusion

The establishment of the CE mark for FertilAI’s predictive tools marks a historic moment in the intersection of technology and healthcare. By empowering fertility clinics with precise AI-driven insights, FertilAI is poised to make significant improvements in reproductive health services, addressing critical needs in a rapidly evolving medical landscape.